Perspectives and Insights From MF experts
The resources on this page offer information and insights about Jakafi® (ruxolitinib) and treatment of patients with intermediate- or high-risk myelofibrosis (MF), including primary MF, post–polycythemia vera MF, and post–essential thrombocytopenia MF. Be sure to check back regularly as new materials will be added as they become available.
Dr Mesa’s Perspective:
Spleen Volume Reduction and Long-Term Survival in MF

Dr Mesa’s Perspective:
Spleen Volume Reduction and
Long-Term Survival in MF
Hematologist-oncologist Dr Ruben Mesa shares how he uses Jakafi to actively manage his patients with MF who have splenomegaly and discusses how intervening at diagnosis may impact spleen volume and overall survival.
Dr Mesa’s Perspective:
Managing Anemia in Patients With MF

Dr Mesa’s Perspective:
Managing Anemia in Patients With MF
Hematologist-oncologist Dr Ruben Mesa discusses the importance of intervening with Jakafi regardless of anemia status and his approach to managing baseline and new-onset anemia during treatment.

Dr Fazal’s Perspective:
Spleen and Overall Survival in MF

Dr Fazal’s Perspective:
Spleen and Overall Survival in MF
Hematologist and bone marrow transplant physician Dr Salman Fazal explains why the data for Jakafi give him the confidence to prescribe treatment at diagnosis for his appropriate patients.